Company Overview and News
Last week, the Federal Reserve decided to keep US interest rates unchanged, marking its 96th month of life at the zero bound. Apparently, for all of its "data dependence," the Fed feels the economy could still benefit from *just* a little more of its ZIRP happy juice.
Often, a few top officials speak publicly in favor of increasing interest rates. Then days later, another one of them talks down a rate hike. These conflicting messages from the Fed's top leadership continue to hurt public confidence in the Fed, experts say.
Allianz (OTCQX:AZSEY) (OTCQX:ALIZF) is one of the biggest insurance companies in the world. The company also has an asset management division with almost $2 trillion in assets under management.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MADRID, 5 de septiembre de 2016 /PRNewswire/ -- La agencia internacional A.M. Best ha confirmado el rating de solidez financiera A- (Excelente) de SOLUNION y su calificación crediticia de emisor de "a-", ambos con perspectiva estable.
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Altech Chemicals Ltd (ASX:ATC) will reduce the cost of debt required for the proposed high purity alumina (HPA) plant in Malaysia through a restructure. By increasing the component of debt provided by KfW IPEX-Bank from Germany, Altech reduces the uncovered debt amount. With the restructure, total project debt of US$70 million will be required, composed of US$60 million from KfW IPEX-Bank and the balance of US$10 million remaining uncovered.
MADRID, 12 de agosto de 2016 /PRNewswire/ -- Los Juegos Olímpicos generarán un leve crecimiento y empleo a corto plazo en Brasil, pero su impacto neto será negativo para el país anfitrión, según se desprende del análisis de SOLUNION, compañía experta en seguros de crédito, a partir de las previsiones de su accionista Euler Hermes. En medio de una tendencia de aumento de deuda pública, acoger las Olimpiadas incrementará el número de insolvencias empresariales en el estado de Río de Janeiro y generará presiones inflacionistas visibles hasta 2020.
Altech Chemicals Ltd (ASX:ATC) has now appointed due diligence consultants to undertake the definitive technical, market and legal review on the high purity alumina (HPA) project in Western Australia. The appointment was made on behalf of the proposed financier, Germany’s government-owned KfW IPEX-Bank supported by German export credit agency Euler Hermes. Due diligence activities have now progressed to the next stage and site visits were conducted last week by the various consultants.
Federal Reserve officials this week likely will point to growing signs that the economy is improving enough that at least one rate hike will be warranted by year's end.
International institutions downgraded their outlooks for the euro zone economy on Tuesday following Britain’s shock vote to leave the European Union but said the real impact of Brexit will hinge on how political leaders handle future talks with London.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...